Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Gene therapy for high grade gliomas
Autore:
Alavi, JB; Eck, SL;
Indirizzi:
Hosp Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA Hosp Univ Penn Philadelphia PA USA 19104 ncol, Philadelphia, PA 19104 USA
Titolo Testata:
EXPERT OPINION ON BIOLOGICAL THERAPY
fascicolo: 2, volume: 1, anno: 2001,
pagine: 239 - 252
SICI:
1471-2598(200103)1:2<239:GTFHGG>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
WILD-TYPE P53; CYTOSINE DEAMINASE GENE; MALIGNANT BRAIN-TUMORS; POSITRON-EMISSION-TOMOGRAPHY; PHASE-I TRIAL; THYMIDINE KINASE; GLIOBLASTOMA-MULTIFORME; RECURRENT GLIOBLASTOMA; VIRUS MUTANT; HERPES-VIRUS;
Keywords:
ganciclovir; gene therapy; glioma; prodrug activation; p53 mutation; thymidine kinase; vectors;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
65
Recensione:
Indirizzi per estratti:
Indirizzo: Alavi, JB Hosp Univ Penn, Dept Med, Div Hematol Oncol, 3400 Spruce St,16 Penn Tower,Philadelphia, PA 19104 USA Hosp Univ Penn 3400 Spruce St,16 Penn Tower Philadelphia PA USA 19104
Citazione:
J.B. Alavi e S.L. Eck, "Gene therapy for high grade gliomas", EXPERT OP B, 1(2), 2001, pp. 239-252

Abstract

High grade gliomas in adults are devastating diseases, with very poor survival despite their lack of distant metastases. Local treatments, such as surgical resection and stereotactic radiosurgery, have been most successful, whereas systemic therapy (for example, chemotherapy and immunotherapy) havebeen rather disappointing. Several gene therapy systems have been successful in controlling or eradicating these tumours in animal models and are nowbeing tested as a logical addition to current clinical management. This review describes the gene therapy clinical protocols that have been completedor that are ongoing for human gliomas. These include the prodrug activating system, herpes simplex thymidine kinase (HSVtk)/ganciclovir (GCV), utilising either retrovirus vector producer cells or adenovirus vectors; adenovirus. mediated p53 gene transfer; adenovirus mediated IFN-beta gene transfer and oncolytic herpes virus and adenovirus. vectors. To date, all of the clinical studies have used direct injection of the vector into the glioma. ThePhase I clinical studies have demonstrated low to moderate toxicity and variable levels of gene transfer and in some cases anti-tumour effect. Futuredirections will rely upon improvements in gene delivery as well as gene therapies and combinations of gene therapy with other treatment modalities.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 13:05:47